This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...

Current health news includes a push for board overhaul at Avantor by Engine Capital, Ab&B Bio-Tech's share surge during its ...

Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.

Novo Nordisk A/S (NYSE:NVO) is among the. Novo Nordisk A/S (NYSE:NVO) lowered its operating profit growth projections to ...

WeightWatchers is now only offering Wegovy while other telehealth providers defiantly hang on to compounded alternatives.

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

STORY: Novo Nordisk is ramping up lawsuits against U.S. companies selling cheaper versions of its weight-loss drug Wegovy. But one firm remains conspicuously absent: Hims & Hers.This telehealth ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

There has been a 27% YoY increase in sales of weight-loss drugs, especially after the launch of Mounjaro and Novo Nordisk's ...